Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]MNI-1020 PET Imaging in Alzheimer's Disease
NCT03239561Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [18F] JNJ-64326067 in Alzheimer's disease (AD), sponsored by Janssen Pharmaceutical. Primary endpoints: Standardized Uptake Value Ratio, Plasma Concentration of [18F]MNI-1020 and 2 more. Started Sep 2017; status: completed.
02
Drugs
[18F] JNJ-64326067
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03239561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03239561.